Suchergebnisse - "DENDA, T"

PubPharm (51)

1

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

enthalten in: ESMO open | 2022

von Okamoto, W. | Sakai, K. | Makiyama, A. | +16

2

REVERCE : a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Shitara, K. | Yamanaka, T. | Denda, T. | +15

3

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE) : a randomized, open-label, phase III, noninferiority trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Yamada, Y. | Denda, T. | Gamoh, M. | +17

4

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Yamazaki, K. | Nagase, M. | Tamagawa, H. | +45

CommentIn: Ann Oncol. 2016 Aug;27(8):1372-4. - PMID 27358377

5

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

enthalten in: Annals of oncology | 2016

von Yamazaki, K. | Nagase, M. | Tamagawa, H. | +45

6

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

enthalten in: Annals of oncology | 2016

von Yamazaki, K. | Nagase, M. | Tamagawa, H. | +45

7

Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer

enthalten in: Annals of oncology | 2016

von Yamazaki, K. | Yoshino, T. | Shinozaki, E. | +15

8

217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer

enthalten in: Annals of oncology | 2016

von Yamazaki, K. | Kito, Y. | Esaki, T. | +6

9

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy : the randomized phase III EAGLE study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Iwamoto, S. | Takahashi, T. | Tamagawa, H. | +17

10

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

enthalten in: Annals of oncology | 2015

von Iwamoto, S. | Takahashi, T. | Tamagawa, H. | +17

1
2
3
4
5
6
Nächster »
[6]